Anti-PD-1/PD-L1 antibodies have also been assessed for their efficacy in the other viral related carcinomas, such as hepatitis B virus (HBV)-related hepatocellular carcinoma (HCC) [16]. This evidence concerns the gene RPL17 and hepatocellular carcinoma.